Biocad enters deal for exporting rituximab biosimilar to Turkey The Pharma Letter Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export of rituximab active pharmaceutical ingredients (APIs) produced by the company with Kocak Farma, a leading Turkish drugmaker with strong presence ... |
